Rossari Biotech Q2 FY27 Results (NSE: ROSSARI)

· Analysis by Alpha Inflection

Signal: Growth decelerated

Rossari Biotech Q2 FY27 key financials
MetricValueYoYQoQ
Revenue₹697.56 Cr+19.0%+0.1%
Net profit₹38.91 Cr+5.5%
EPS₹7.02+5.4%
EBIT margin12.6%

P&L walk

Revenue grew 19.0% YoY to ₹6,975.60 million, EBITDA increased 18.4% to ₹875.73 million with margin nearly flat at 12.6%, and PAT rose only 5.5% to ₹389.07 million as depreciation increased 65.0% and finance costs rose 42.4%.

View original filing

Research and educational content only. Not investment advice.